胃と腸48巻5号

2013年05月発行

特集 炎症性腸疾患 2013 ノート

炎症性腸疾患におけるリンパ増殖性疾患

著者： 岡崎和一¹ 深田憲将¹ 安藤祐吾¹ 大宮美香¹ 岡崎敬¹ 栗島亜希子¹ 松下光伸¹

所属機関： ¹関西医科大学内科学第三講座（消化器肝臓内科）

ページ範囲：P.763 - P.769

海外における潰瘍性大腸炎やCrohn病などの炎症性腸疾患（IBD）患者では，長期の臨床経過に加え，免疫調節薬や抗TNF-α抗体などの使用により，リンパ増殖症のリスクの可能性が報告されている．しかし，中にはそれらを否定する報告もあり，議論のあるところであるが，わが国における実態は不明である．文献や厚生労働省難治性腸管障害調査研究班による全国アンケート調査の検討では，IBD患者におけるリンパ血液疾患増殖症の発症リスクは必ずしも高くはないが，今後の検討が必要であると思われる．

参考文献

1）Collins PD Mpofu C, Watson AJ, et al. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 19 : CD000279, 2006

2）Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 16 : CD000545, 2010

3）Jones JL, Loftus EV Jr. Lymphoma risk in inflammatory bowel disease : is it the disease or its treatment ? Inflamm Bowel Dis 13 : 1299-1307, 2007

4）Kamdar KY, Rooney CM, Heslop HE, et al. Post-transplant lymphoproliferative disease following liver Transplantation. Curr Opin Organ Transplant 16 : 274-280, 2011

5）Ekbom A, Helmick C, Zack M, et al. Extracolonic malignancies in inflammatory bowel disease. Cancer 67 : 2015-2019, 1991

6）Persson PG, Karlén P, Bernell O, et al. Crohn's disease and cancer : a population-based cohort study. Gastroenterology 107 : 1675-1679, 1994

7）Karlén P, Löfberg R, Broström O, et al. Increased risk of cancer in ulcerative colitis : a population-based cohort study. Am J Gastroenterol 94 : 1047-1052, 1999

8）Loftus EV Jr, Tremaine WJ, Habermann TM, et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 95 : 2308-2312, 2000

9）Palli D, Trallori G, Bagnoli S, et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology 119 : 647-653, 2000

10）Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease : a population-based study. Cancer 91 : 854-862, 2001

11）Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 121 : 1080-1087, 2001

12）Winther KV, Jess T, Langholz E, et al. Long-term risk of cancer in ulcerative colitis : a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2 : 1088-1095, 2004

13）Jess T, Winther KV, Munkholm P, et al. Intestinal and extra-intestinal cancer in Crohn's disease : follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 19 : 287-293, 2004

14）Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 54 : 617-622, 2005

15）von Roon AC, Reese G, Teare J, et al. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum 50 : 839-855, 2007

16）Vos AC, Bakkal N, Minnee RC, et al. Initiative on Crohn's and Colitis（ICC）. Risk of malignant lymphoma in patients with inflammatory bowel diseases : a Dutch nationwide study. Inflamm Bowel Dis 17 : 1837-1845, 2011

17）Beaugerie L, Brousse N, Bouvier AM, et al. CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease : a prospective observational cohort study. Lancet 374 : 1617-1625, 2009

18）Sokol H, Beaugerie L, Maynadié M, et al. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis 18 : 2063-2071, 2012

19）Lakatos PL, Lovasz BD, David G, et al. The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases : Results from a population-based cohort in Eastern Europe. J Crohns Colitis（epub ahead of print）, 2012

20）Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 106 : 2146-2153, 2011

21）Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 78 : 44-49, 1985

22）Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 343 : 1249-1252, 1994

23）Korelitz BI, Mirsky FJ, Fleisher MR, et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 94 : 3248-3253, 1999

24）Farrell RJ, Ang Y, Kileen P, et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 47 : 514-519, 2000

25）Fraser AG, Orchard TR, Robinson EM, et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 16 : 1225-1232, 2002

26）Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54 : 1121-1125, 2005

27）Glazier KD, Palance AL, Griffel LH, et al. The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol 39 : 21-26, 2005

28）Sultan K, Korelitz BI, Present D, et al. Prognosis of lymphoma in patients following treatment with 6-mercaptopurine/azathioprine for inflammatory bowel disease. Inflamm Bowel Dis 18 : 1855-1858, 2012

29）Ashworth LA, Billett A, Mitchell P, et al. Lymphoma risk in children and young adults with inflammatory bowel disease : analysis of a large single-center cohort. Inflamm Bowel Dis 18 : 838-843, 2012

30）Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease : a cautionary tale ? Inflamm Bowel Dis 13 : 1024-1030, 2007

31）Drini M, Prichard PJ, Brown GJ, et al. Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease.　Med J Aust 189 : 464-465, 2008

32）http://www.fda.gov/Safety/MedWatch/SafetyInfor　mation/SafetyAlertsforHumanMedicalProducts/ucm175843.htm（URL最終確認 : 2013年3月）

33）Parakkal D, Sifuentes H, Semer R, et al. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy : expanding the groups at risk. Eur J Gastroenterol Hepatol 23 : 1150-1156, 2011

34）岡崎和一，深田憲将，松下光伸，他．我が国におけるIBD患者のリンパ増殖性疾患の現状に関する実態調査．厚生労働科学研究費補助金難治性疾患克服研究事業　難治性炎症性腸管障害に関する調査研究．平成22年度総括・分担研究報告書．2011